BofA analysts are bullish on this German medtech name ahead of its full-year earnings report.
Get this delivered to your inbox, and more info about our products and services.
The bank pointed to recent M&A success as a catalyst for the stock.
The investment bank upgraded the pharma stock to overweight from equal weight.
Chart analyst Frank Cappelleri breaks down the technical outlook on the biotech stock.
Jay Woods breaks down the charts in Steris.
David Keller breaks down the technicals on this biotech giant.
The bank initiated the stock with an outperform rating.
